Vineet Agra's questions to Alvotech SA (ALVO) leadership • Q1 2024
Question
An analyst from Citi, likely Vineet Agra, asked about the significance of the interchangeability designation for gaining market share, especially since a competitor appears unconcerned about not having it and the FDA is reportedly pushing for more general labeling.
Answer
Chief Commercial Officer Anil Okay responded that Alvotech views interchangeability as a 'significant advantage.' He emphasized that the benefit extends beyond the designation itself to the market exclusivity it provides, which for Alvotech's HUMIRA biosimilar lasts until at least May 2025. He added that interchangeability is very helpful in reducing the 'friction of conversion' for patients.